PC8
PC8 is a selective dual inhibitor of PARP1/CDK6, with an IC50 of 0.126 μM for PARP1 and 0.197 μM for CDK6. PC8 does not alter PARP1 expression, but reduces the expression of its downstream target PAR. PC8 inhibits the canonical Wnt/β-catenin signaling pathway. PC8 induces intracellular ROS accumulation and exacerbates DNA damage. PC8 inhibits the proliferation of triple-negative breast cancer (TNBC) cells. PC8 can be used for the research of triple-negative breast cancer.
For research use only. We do not sell to patients.
- Formula: C28H32BrN7O2
- Molecular Weight:578.50
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All DNA/RNA Synthesis Isoforms
More
Biological Activity
Description
IC50 & Target
[1]|
CDK6 0.197 μM (IC50) |
PARP1 0.126 μM (IC50) |
In Vitro
PC8 potently and selectively inhibits purified PARP1 with an IC50 of 0.126 μM, whereas it shows weak inhibitory activity against PARP2 (IC50 = 0.824 μM)[1].
PC8 potently inhibits purified CDK6 with an IC50 of 0.197 μM, and exhibits only limited activity against most other members of the CDK family[1].
PC8 (72 h) potently inhibits the proliferation of three triple-negative breast cancer (TNBC) cell lines, namely MDA-MB-231 (IC50 = 1.14 μM), MDA-MB-468 (IC50 = 1.25 μM), and BT-549[1].
PC8 (0.5-1.5 μM; 48 h) inhibits the downstream pathway of PARP1 and induces DNA damage in BT-549 triple-negative breast cancer (TNBC) cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:BT-549 TNBC cells
-
Concentration:0.5-1.5 μM
-
Incubation Time:48 h
-
Result:Did not alter PARP1 expression, but reduced PAR expression.
Reduced CDK6 expression slightly and RB1 expression markedly.
Reduced RAD51 and BRCA1 levels, and increased γ-H2AX levels.
Upregulated E-cadherin expression and downregulated N-cadherin and Vimentin expression.
Reduced expression of β-catenin, Axin2, P-GSK3β, and Wnt3a.
Chemical Information
-
Molecular Weight 578.50
-
Formula C28H32BrN7O2
-
SMILES
O=C1C(Br)=C(C)C2=CN=C(N[C@@H]3CN(CC4=CC(N5)=C(N=C4)C=C(CC)C5=O)CC3)N=C2N1C6CCCC6
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Breast Cancer Modeling
Breast cancer is a heterogeneous cancer, and it has been distinguished into four subtypes: luminal A, luminal B, HER2-positive and basal-like. Molecular mutations, epigenetic alterations, hormone exposure and immune microenvironment are related to the progression of breast cancer.
-
Genotoxicity/Mutagenicity Study
The bacterial reverse mutation assay detects point mutations that restore amino-acid prototrophy in auxotrophic Salmonella typhimurium or Escherichia coli tester strains; after exposure to a test article, mutagenic activity is read out as an increased number of revertant colonies on minimal agar compared with the vehicle control. The assay uses tester strains with different mutation targets so that base-substitution and frameshift mutagens can be detected, and testing is performed with and without exogenous mammalian metabolic activation because some chemicals require biotransformation to become mutagenic.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)